{"id":827268,"date":"2025-03-18T16:36:37","date_gmt":"2025-03-18T20:36:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"},"modified":"2025-03-18T16:36:37","modified_gmt":"2025-03-18T20:36:37","slug":"immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","title":{"rendered":"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, March  18, 2025  (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.<\/p>\n<p>Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.<\/p>\n<p>\n        <strong>Webcast Details<\/strong>\n      <\/p>\n<p>The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. <strong>Please click <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4I1omQVOQ6QJOQ9iVtqlfgGIMYEZDFTzJZ-EL3g2QZMzi_1v0ZyuQcIvJLKfA1vHlONQvhhriuUE8Ra596jN2-chHs82ocu4cZFGwQyNufg=\" rel=\"nofollow\" target=\"_blank\"><strong>here<\/strong><\/a><strong> to register for the event.<\/strong> The live webcast will also be available under the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pzsUnwXaK7w--gBtFXHwYgWALh-of2wgeBU05VG4Raix2ZkVHagUIorNdnk9XCTdywTTBQHNchwo2-gInCgwIr60XTP79wRDdNj22nF27YBwhf_LiaDMpBXiTh0zI0X2\" rel=\"nofollow\" target=\"_blank\">News &amp; Events<\/a> section of Immunovant\u2019s website. A replay of the event and presentation will be available immediately following the event.<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>Immunovant,<\/strong><br \/>\n        <strong>Inc.<\/strong>\n      <\/p>\n<p>Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9c2eIUTwpTATEmKFLdqKv3Ny7VHj19eFeV4mhGePar6ODI_3SdU-qD6_pzQcVZzBiPZ5K7oxdAzGMKBVeZarzQSeOxFbi6nhN5SmdwEXTY=\" rel=\"nofollow\" target=\"_blank\">immunovant.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Renee Barnett, MBA <br \/>Chief Financial Officer <br \/>Immunovant, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lKw1K5YuqZwGM9xEmIfQ5mbbSvaOe3sIPxNjV5bMY6h0soBa-Ath2O63Bze-lNhySu5Auw8RTjl0i_lCYNE8Iz5CVuYMq3nAbf4LqHjHXY8=\" rel=\"nofollow\" target=\"_blank\">info@immunovant.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmI1YzUzMTgtMTQzMi00ZmUxLThiYjAtYjc4YTAwNmViNGY3LTExMzc0MTUtMjAyNS0wMy0xOC1lbg==\/tiny\/Immunovant-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827268","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under &hellip; Continue reading &quot;Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T20:36:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs\",\"datePublished\":\"2025-03-18T20:36:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\"},\"wordCount\":233,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\",\"name\":\"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=\",\"datePublished\":\"2025-03-18T20:36:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","og_locale":"en_US","og_type":"article","og_title":"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk","og_description":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under &hellip; Continue reading \"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T20:36:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs","datePublished":"2025-03-18T20:36:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"},"wordCount":233,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","name":"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=","datePublished":"2025-03-18T20:36:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjYzOCM2ODEyMjQ2IzIxMjU4NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827268"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827268\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}